Silexion Therapeutics Corp SEC filings SLXN
Silexion Therapeutics Corp has 279 filings in SEC EDGAR's recent list, going back to May 9, 2024. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (bylaw or fiscal year change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Sep 28, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 19, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 18, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jun 23, 2026 | — |
| 4 | Insider transaction | Jun 8, 2026 | Jun 4, 2026 |
| 4 | Insider transaction | Jun 8, 2026 | Jun 4, 2026 |
| 4 | Insider transaction | Jun 8, 2026 | Jun 4, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 29, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 4 | Insider transaction | Mar 30, 2026 | Mar 26, 2026 |
| 4 | Insider transaction | Feb 25, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| 4 | Insider transaction | Jan 27, 2026 | Aug 7, 2025 |
| 4 | Insider transaction | Dec 31, 2025 | Feb 9, 2025 |
| 4 | Insider transaction | Dec 31, 2025 | Feb 9, 2025 |
| 4 | Insider transaction | Dec 31, 2025 | Feb 9, 2025 |
| 4 | Insider transaction | Dec 31, 2025 | Feb 9, 2025 |
| 4 | Insider transaction | Dec 31, 2025 | Feb 9, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Sep 23, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 18, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 17, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Sep 15, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 15, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 15, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jun 26, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 13, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 12, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 10, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 23, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 21, 2025 | — |
| 3 | Initial insider ownership | Dec 18, 2024 | Dec 10, 2024 |
| SC 13D | Ownership over 5% (active) | Nov 20, 2024 | — |
| SC 13D | Ownership over 5% (active) | Aug 22, 2024 | — |
| SC 13D | Ownership over 5% (active) | Aug 22, 2024 | — |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
| 3 | Initial insider ownership | Aug 15, 2024 | Aug 15, 2024 |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SLXN (Nasdaq), SLXNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2022416
- Former names
- Biomotion Sciences (until Aug 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.